The literature has indicated that immunotherapy targeting PD-1 and CTLA-4 specifically increases CXCL9 and CXCL10 from tumor-associated macrophages in tumor tissues, whereas CXCL9 and CXCL10 are induced by IFNγ in the tumor microenvironment [27]. The gene discussed is CXCL9; the disease is neoplasm.